Literature DB >> 34534421

Long-Acting Injectable Antipsychotic Medication Plus Customized Adherence Enhancement in Poor Adherence Patients With Bipolar Disorder.

Martha Sajatovic1,2,3, Jennifer B Levin2, Luis F Ramirez2, Kristin A Cassidy1,2, Nora McNamara2, Edna Fuentes-Casiano2, Betsy Wilson1,2, Deionte Appling2, Farren B S4.   

Abstract

Objective: People with bipolar disorder (BD) often have difficulty with medication adherence. This pilot trial combined a behavioral customized adherence enhancement (CAE) approach with long-acting injectable (LAI) antipsychotic medication and assessed effects on adherence, BD symptoms, and functional status.
Methods: This 6-month prospective, uncontrolled trial of the intervention (CAE with LAI) in 30 poorly adherent individuals with BD assessed adherence using the Tablets Routine Questionnaire (TRQ) and symptoms using the Brief Psychiatric Rating Scale (BPRS), Young Mania Rating Scale (YMRS), Hamilton Depression Rating Scale (HDRS), and Clinical Global Impressions (CGI). Functioning was assessed via the Social and Occupational Functioning Assessment Scale (SOFAS) and Global Assessment of Functioning (GAF). Assessments were conducted at screening, baseline, week 12, and week 24 (6 months). The LAI was aripiprazole once monthly. The study was conducted between April 2018 and May 2020.
Results: The mean age of the sample was 49.5 years (SD = 9.3), and 56.7% were Black. Nine individuals (30%) terminated the study prematurely, 1 due to side effects (tremor). The mean LAI dose was 314.3 mg (SD = 96.4). The proportion of missed medications in the past week (mean TRQ) from screen to 24 weeks significantly improved from 50.1% (SD 24.8) to 16.9% (SD = 27.0) (P < .001), and past month TRQ improved from 40.6% (SD = 23.8) to 19.2% (SD = 24.0) (a trend for significance, P = .0599). TRQ change from baseline to 24 weeks was not significant. There were significant improvements on the BPRS (P < .001), MADRS (P = .01), YMRS (P < .001), CGI (P < .001), SOFAS (P < .001), and GAF (P < .001).
Conclusion: A personalized intervention to address adherence barriers combined with LAI can improve recovery outcomes in high-risk individuals with BD. Trial Registration: ClinicalTrials.gov Identifier: NCT03408873. © Copyright 2021 Physicians Postgraduate Press, Inc.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 34534421     DOI: 10.4088/PCC.20m02888

Source DB:  PubMed          Journal:  Prim Care Companion CNS Disord        ISSN: 2155-7780


  2 in total

1.  Combining Medication Adherence Support Plus Long-Acting Injectable Antipsychotic Medication: A Post-Hoc Analysis of 3 Pilot Studies.

Authors:  Thomas Canales; Samuel Rodman; Danette Conklin; Kaylee Sarna; Martha Sajatovic; Jennifer B Levin
Journal:  Psychopharmacol Bull       Date:  2022-06-27

2.  An interventional pilot of customized adherence enhancement combined with long-acting injectable antipsychotic medication (CAE-L) for poorly adherent patients with chronic psychotic disorder in Tanzania.

Authors:  Jessie Mbwambo; Sylvia Kaaya; Isaac Lema; Christopher J Burant; Catherine Magwiza; Kim Madundo; Godwin Njiro; Carol E Blixen; Kristin A Cassidy; Jennifer B Levin; Martha Sajatovic
Journal:  BMC Psychiatry       Date:  2022-01-27       Impact factor: 3.630

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.